Great strides have been made in recent years on the development of tau immunotherapies for Alzheimer’s disease and other tauopathies. Multiple animal studies by several groups have shown efficacy of various active and passive approaches in reducing pathological tau proteins. Clinical trials are clearly warranted and a few have already been initiated. However, much remains to be clarified regarding the mechanisms of action and how efficacy can be improved and potential toxicity minimized. These are exciting times for the field and will hopefully lead to an effective therapy in the near future.
CITATION STYLE
Sigurdsson, E. M. (2016). Tau immunotherapy. In Methods in Pharmacology and Toxicology (Vol. PartF1, pp. 109–120). Humana Press Inc. https://doi.org/10.1007/978-1-4939-3560-4_8
Mendeley helps you to discover research relevant for your work.